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Carcinoembryonic antigen (CEA)–related cell 
adhesion molecule 1 (CEACAM1) is a member 
of the CEA-family of Ig-like transmembrane 
proteins  (Gray-Owen  and  Blumberg,  2006). 
CEACAM1 is expressed in a wide range of 
normal tissues and tumors. It is characterized 
by significant alternate splicing, which gener-
ates isoforms that differ in cytoplasmic tail (CT) 
length and the number of extracellular Ig-like 
domains; these isoforms are named accordingly. 
The majority of CEACAM1 isoforms possess 
either a long (CEACAM1-L) CT or a short 
(CEACAM1-S) CT. CEACAM1-L isoforms 
predominate  in  most  cell  types,  and  contain 
two  immunoreceptor  tyrosine-based  inhibitory 
motifs  (ITIMs;  Gray-Owen  and  Blumberg, 
2006). Early studies have shown that CEACAM1 
expression is often lost in sporadic colorectal 
and prostate cancers in humans and, consistent 
with this, tumor size and number are increased 
in Ceacam1/ mice exposed to azoxymethane 
administration (Leung et al., 2006). There-
fore, CEACAM1-L has been labeled a tumor   
suppressor.  However,  more  recent  clinical 
studies in a wide variety of human tumors, in-
cluding  melanoma  (Gambichler  et  al.,  2009; 
Markel et al., 2010) and cancers of the lung 
(Obrink, 2008), pancreas (Simeone et al., 2007), 
bladder (Tilki et al., 2009), colon (Kang et al., 
2007), and thyroid (Liu et al., 2007), have ob-
served that high levels of CEACAM1 expres-
sion on tumor cells directly correlates with poor 
prognosis and tumor metastasis.
To seek a biological basis for these clinical 
observations, we investigated the consequences 
of tumor cell expression of CEACAM1 on 
immune-surveillance. We focused our atten-
tion on the interactions between CEACAM1 
and a receptor–ligand system that is expressed 
on both tumor-infiltrating lymphocytes (TILs) 
and tumors; namely, NK gene complex group 2 
(NKG2)  member  D  (NKG2D,  gene  name 
KLRK1) and its ligands (NKG2DL). NKG2D is 
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Although carcinoembryonic antigen (CEA)–related cell adhesion molecule 1 (CEACAM1) 
has been viewed as a tumor suppressor, increasing clinical evidence shows that high levels 
of CEACAM1 expression on tumors correlates with poor prognosis and high risk of metastasis. 
Here, we examined the consequences of CEACAM1 expression on tumor cells. We show 
that tumor cell–associated CEACAM1 causes intracellular retention of various NKG2D 
ligands in mouse and human tumor cells. CEACAM1-silenced tumor cells expressed more 
cell surface NKG2D ligands and exhibited greater sensitivity to natural killer cell–mediated 
cytolysis in vitro and rejection in vivo. Our studies reveal a novel mechanism through which 
CEACAM1-bearing tumor cells may escape immune-surveillance.
© 2011 Chen et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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CEACAM1 on B16F10 tumor cells did not affect in vivo 
tumor growth (Fig. 1 b). Because T cells and NK cells play 
an  important  role  in  antitumor  immunity,  we  conducted 
studies in RAG2-deficient mice, which lack T and B cells. As 
shown in Fig. 1 c, the tumor growth of CEACAM1-silenced 
MC38 cells in RAG2-deficient mice was retarded in com-
parison  to  the  growth  observed  with  nonsilenced  MC38 
cells. These studies in RAG2-deficient mice are consistent 
with an important role for NK cells in the enhanced immune 
protection against MC38 tumor cells.
To further confirm that down-regulation of CEACAM1 
expression on MC38 cells results in increased sensitivity to NK 
cell–mediated immunity, we conducted in vitro cytotoxicity 
assays. Consistent with observations in vivo, CEACAM1-
silenced MC38 cells exhibited increased sensitivity to primary 
naive NK cell–mediated cytolysis in comparison to nonsilenced 
MC38 cells (Fig. 1 d). Consistent with in vivo observations 
(Fig. 1 b), B16F10 cells, which are MHC class I–negative 
(Lim et al., 1998), were not lysed by NK cells (Fig. 1 d), indicat-
ing an insufficiency or absence of MHC class I–independent 
activating ligands on the cell surface of these cells or the pres-
ence of ligands for other inhibitory receptors on NK cells.
an activating NK receptor expressed on all NK cells and 
CD8+ T cells, as well as a set of CD4+ T cells (Lanier, 2008). 
NKG2D plays a pivotal role in NK cell– and T cell–mediated 
immunity against cancers and infections, as well as in the de-
velopment of autoimmune diseases (Lanier, 2008). NKG2D 
exerts its effects through recognition of its cognate ligands on 
target cells, resulting in their cytolytic destruction.
The ligands that bind to human NKG2D are MHC class I–
related molecule A and B (MICA and MICB) and UL-16–
binding  proteins  (ULBPs).  In  mouse,  NKG2D  ligands 
(NKG2DL) include retinoic acid early inducible cDNA clone 1   
(Rae-1), murine UL16-binding protein 1 (MULT1), and 
the H60 family of glycoproteins. Expression of NKG2DL on 
the cell surface is tightly regulated at transcriptional and 
posttranscriptional levels (Spies, 2008). Moreover, tumors 
or virally infected cells have evolved other mechanisms to 
escape NKG2D- and NKG2DL-mediated immune surveil-
lance (Wu et al., 2003; Stern-Ginossar et al., 2007; Champsaur 
and Lanier, 2010). Tumor cells shed autonomous NKG2DL, 
leading to insensitivity of tumor cells to cytolysis mediated by 
NK cells and CD8+ T cells (Groh et al., 2002). Tumor cells 
also retain NKG2DL intracellularly (Fuertes et al., 2008). 
However, the mechanism is unknown.
Here, we show that, like cytomegalovirus (CMV)-derived 
proteins  which  retain  and  inhibit  maturation  of  certain 
NKG2DL (Wu et al., 2003; Champsaur and Lanier, 2010), 
CEACAM1 can mediate a similar process in tumor cells, result-
ing in diminished sensitivity to NKG2D-dependent cytoly-
sis by NK cells. In so doing, this study demonstrates that 
CEACAM1  attenuates  antitumor  immunity  by  disabling 
NKG2DL function on tumor cells.
RESULTS AND DISCUSSION
Tumor cell–autonomous CEACAM1 differentially  
regulates tumor cell sensitivity to NK cell–mediated 
cytolysis and tumor rejection
High expression of CEACAM1 on a variety of tumor cell 
types has been shown to directly correlate with a worse prog-
nosis and risk of tumor metastasis (Sienel et al., 2003; Kang 
et al., 2007; Simeone et al., 2007; Dango et al., 2008; Xi et al., 
2008; Tilki et al., 2009). We therefore sought to define a bio-
logical basis for this observation and examined the functional 
consequences of CEACAM1 expression on tumor cells. To 
this end, we silenced CEACAM1 expression on mouse 
tumor cell lines MC38 (colon cancer) and B16F10 (mela-
noma) derived from C57BL/6 (B6) mice. As shown (Fig. 1 a), 
both total and cell surface expression of CEACAM1 was de-
creased to a similar extent in MC38 and B16F10 cells that ex-
pressed CEACAM1-target short hairpin RNA (CC1shRNA), 
but not a control nontargeted shRNA (nonTshRNA). We 
then tested the effect of silencing tumor cell CEACAM1 on 
in vivo tumor growth. Interestingly, when subcutaneously 
inoculated into WT B6 mice, the growth of CEACAM1-
silenced MC38 tumors (CC1shRNA) was significantly di-
minished  in  comparison  to  the  growth  of  CEACAM1 
nonsilenced (nonTshRNA) MC38 tumor cells, whereas silencing 
Figure 1.  Silencing CEACAM1 differentially sensitizes tumor cells to 
NK cell–mediated in vitro cytolysis and in vivo tumor rejection.  
(a) Silencing CEACAM1 expression in mouse MC38 and B16F10 cells. (left) 
Immunoblot (IB) results. Parental, nontransduced cells; CC1shRNA, mouse 
CEACAM1 shRNA; nonTshRNA, control nontargeting shRNA. (right) Flow 
cytometric analysis of CEACAM1 surface expression. Ig, isotype-matched 
control Ig. The numbers in flow cytometric data are mean fluorescence 
intensity (MFI; applied to all flow cytometric data). (b and c) Tumor growth 
in wild type (WT; b) and Rag2/ B6 (c) mice. Tumor size (two dimensions;  
n ≥ 6; mean ± SEM; *, P < 0.05; **, P < 0.01) measured by calipers. (d) Mouse 
NK cell–mediated cytotoxicity at various E/T (effector/target cells) ratios. 
Standard 51Cr release 4-h cytotoxicity assay and calculation of specific  
cytolysis percentages (triplicate; mean ± SEM; *, P < 0.05) was performed. 
Yac1 is a positive control for mouse NK cell–mediated cytolysis. All results 
are representative of three or four independent experiments.JEM Vol. 208, No. 13  2635
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antibody, but not control antibody. In fact, the ability of NK 
cells to lyse MC38 cells in either the presence or absence of 
CEACAM1 silencing was totally dependent on NKG2D-
mediated lysis, given the ability of 5 µg/ml of anti-NKG2D 
antibody  to  almost  completely  eliminate  NK  cell  lysis  of 
MC38 cells. This also indicates that MC38 cells either do 
not express or express insufficient quantities of other NK-
activating receptor ligands.
We also confirmed that the increased NKG2DL expres-
sion on CEACAM1-silenced MC38 cells was the factor 
responsible for the increased immune protection. Specifically, 
we examined the ability of RAG2-deficient mice to reject 
CEACAM1-silenced MC38 cells in the presence and absence 
of NKG2D blockade. As shown in Fig. 2 c, blocking NKG2D 
function completely eliminated the increased immune pro-
tection  provided  by  CEACAM1  silencing  of  MC38  cells 
such  that  the  growth  of  MC38  cells  bearing  a  targeting 
(CC1shRNA) or nontargeting (nonTshRNA) shRNA was 
similar in the presence of the blocking anti-NKG2D antibody 
(Fig. 2 c). Collectively, silencing CEACAM1 expression in 
tumor cells enhances NKG2D-mediated antitumor immu-
nity via increased NKG2DL on the tumor cells.
Because NK cells are capable of expressing CEACAM1 
upon activation, which in turn is capable of inhibiting NK 
cell cytolytic function (Markel et al., 2002), it was important 
to examine CEACAM1 expression on the NK cells during 
the 4 h cytotoxicity assay. We observed no CEACAM1 
expression on primary Ceacam1/ and WT mice NK cells 
or on these cells after incubation with target cells during the 
cytotoxicity assay (unpublished data). In addition, NK cells 
from Ceacam1/ and WT mice exhibited an equivalent in-
crease  in  their  ability  to  lyse  CEACAM1-silenced  MC38 
cells (unpublished data). These studies show that the aug-
mentation of NK cell–mediated lysis of CEACAM1-silenced 
MC38 cells was not a result of decreased inhibition caused by 
homophilic interactions between CEACAM1 on tumor cells 
and NK cells. Thus, CEACAM1 expression on MC38 cells 
was mediating a cell-autonomous decrease in the sensitivity 
to NK cell–mediated killing.
Tumor cell–autonomous CEACAM1 down-regulates NKG2DL 
expression and sensitivity to NKG2D-mediated cytolysis
The  aforementioned  studies  suggested  that  CEACAM1 
expression on tumor cells caused decreased access to or 
expression of a tumor-associated ligand capable of activating 
NK  cell  cytolysis.  Among  such  NK-activating  receptors, 
NKG2D has well characterized ligands that are expressed on 
certain  tumor  cells  and  involved  in  antitumor  immunity 
(Diefenbach et al., 2001; Lanier, 2008). Therefore, we inves-
tigated  whether  silencing  CEACAM1  expression  affected 
NKG2DL expression in MC38 and B16F10 cells and the ef-
fects that this had on NK cell–mediated cytolysis. Expression 
of Rae-1 and MULT1 was, indeed, observed on the cell sur-
face of MC38 cells (Fig. 2 a). Moreover, silencing CEACAM1 
expression in MC38 cells resulted in a further and significant 
increase in cell surface expression of Rae-1 and MULT1 
(Fig. 2 a). Importantly, CEACAM1 silencing had no effect 
on the cell surface expression of MHC class I on MC38 cells 
(Fig. 2 a). In contrast, and consistent with the lack of sen-
sitivity to NK cell–mediated cytolysis as a consequence of 
CEACAM1 silencing, no noteworthy expression of either 
NKG2DL (Rae-1 or MULT1) or MHC class I could be 
detected on the cell surface of CC1shRNA or nonTshRNA 
B16F10 cells (Fig. 2 a). These results show that CEACAM1 
expression  is  associated  with  down-regulation  of  multiple 
NKG2DLs on the cell surface of M38 tumor cells.
Therefore, we sought to confirm that the increased ex-
pression of NKG2DL as a consequence of CEACAM1 si-
lencing directly contributed to the enhanced sensitivity of 
CEACAM1-silenced  MC38  cells  to  NK  cell–mediated 
cytolysis. To do so, we examined the in vitro lysis and in vivo 
rejection of CEACAM1-silenced MC38 cells in the presence 
and absence of anti-NKG2D blockade. As shown in Fig. 2 b, 
silencing CEACAM1 expression of MC38 cells resulted in 
increased sensitivity to NK cell–mediated cytolysis in com-
parison to nonsilenced MC38 cells. The enhanced lysis of 
silenced MC38 cells by NK cells was inhibited in a dose-
dependent manner by a blocking anti–mouse NKG2D   
Figure 2.  CEACAM1 regulates NKG2DL expression and NKG2D-
mediated tumor cytolysis and rejection. (a) Flow cytometry analysis of 
CEACAM1, NKG2DL, and MHC-I expression on indicated tumor cells.  
CC1shRNA, mouse CEACAM1 shRNA; nonTshRNA, control nontargeting 
shRNA; Ig, isotype-matched control Ig. (b) Blocking assay for NKG2D-
mediated in vitro cytolysis by indicated antibodies. 51Cr release assay re-
sults (triplicates; mean ± SEM; *, P < 0.05; **, P < 0.01). Effector cells were 
mouse primary NK cells. (c) Blocking assay for NKG2D-mediated in vivo 
tumor rejection was performed in Rag2/ mice with the indicated anti-
bodies (n = 6; mean ± SEM; *, P < 0.05; **, P < 0.01). All results are repre-
sentative of three independent experiments2636 CEACAM1 reduces NKG2D ligand abundance on tumors | Chen et al.
either CEACAM1 isoform resulted in decreased susceptibility to 
NK cell–mediated cytolysis in comparison to that observed 
with cells transfected with an empty vector (Fig. 3 b).
Tumor cells that express more endogenous CEACAM1 
exhibit increased resistance to NK cell–mediated cytolysis
To  investigate  whether  the  observations  obtained  from 
CEACAM1 loss-of-function (silencing) and gain-of-function 
(transfection)  approaches  is  clinically  relevant,  we  analyzed 
CEACAM1 and NKG2DL (MICA/B and ULBP) expression 
on several human melanoma cell lines. We chose to study human 
melanoma cells because melanocytes express CEACAM1 only 
after  they  are  transformed,  implicating  melanoma-associated 
CEACAM1 expression in tumor progression by desensitization 
of the tumor cells to NKG2D-dependent cytolysis. The results 
presented in Fig. 4 a show that, indeed, tumor cells that express 
more CEACAM1 display less MICA/B, as witnessed with the 
MD-AMB435S cell line and vice-versa with the UACC 62 cell 
line. Interestingly, ULBP expression was observed to be indiffer-
ent to the relative levels of CEACAM1 on the tumor cells 
(Fig. 4 a). Moreover, consistent with the results obtained from 
transfection of CEACAM1 into HCT-116 cells (Fig. 3 b), the 
sensitivity of melanoma tumor cells to NK cell–mediated cytoly-
sis was directly proportional to the cell surface expression of 
MICA/B levels and reciprocal to the cell surface display of 
CEACAM1 (Fig. 4 b). To further confirm that difference in 
MICA/B levels on the tumor cells determines their different 
sensitivities to NK cell–mediated cytolysis, we analyzed the effects 
of NKG2D blockade on the cytotoxicity of the melanoma cell 
lines. As shown in Fig. 4 c, the ability of primary NK cells to lyse 
the various tumor cells was nearly completely abolished by an 
anti–NKG2D-blocking antibody in a dose-dependent fashion. 
Collectively, these studies suggest that tumor cell–autonomous 
CEACAM1 expression is biologically important, in part through 
impairment of NKG2D-mediated antitumor immunity.
CEACAM1 regulates Rae-1 glycosylation and retains  
Rae-1 intracellularly
To understand the mechanism involved in the decreased cell 
surface expression of NKG2DL in the presence of CEACAM1, 
we undertook the   
following studies. 
We first observed 
To  determine  whether  human  CEACAM1  expression 
also has an impact upon the expression of MICA or MICB, 
we  examined  the  effects  of  silencing  or  overexpressing 
CEACAM1  in  human  colon  cancer  cell  lines.  In  initial   
experiments,  we  observed  that  HT-29  cells  express  both 
CEACAM1 and MICA/B on the cell surface, and that trans-
duction of HT-29 cells with human CC1shRNA resulted in 
decreased  CEACAM1  expression  and  increased  MICA/B 
expression  compared  with  transfection  of  nonTshRNA 
(Fig. 3 a). Diminishing CEACAM1 expression by shRNA 
did not, however, have any effect on MHC class I expression. 
Conversely, another human colon cancer cell line, HCT116, 
which express endogenous MICA/B, but not endogenous 
CEACAM1, exhibited decreased MICA/B expression as a 
consequence of transfection with the human CEACAM1-3L 
isoform (Fig. 3 a). In contrast, forced expression of CEACAM1-
3L did not result in alterations in the cell surface expression 
of MHC class I (HLA), indicating that CEACAM1 specifi-
cally targets the human NKG2DLs (Fig. 3 a). In another set of 
studies, we observed that HCT116 cells that were transfected 
with human CEACAM1-3S, which possesses the same set of 
extracellular and transmembrane domains as CEACAM1-3L 
but contains a short CT without ITIMs, also caused reduced 
MICA/B expression (Fig. 3 a). These studies show that the 
reduction in MICA/B expression caused by CEACAM1 ex-
pression is independent of ITIM domain-mediated inhibi-
tory signaling. To further confirm these effects of CEACAM1 
expression on MICA/B expression, we tested the effects of 
CEACAM1-3L transfection in two other human cell lines 
(HCT15 and HEK293) and observed that cell surface expres-
sion of MICA/B, but not MHC-I (HLA), was reduced in the 
presence of CEACAM1 expression (unpublished data). It was 
also observed that overexpression of either CEACAM1-L or 
CEACAM1-S in HCT116 cells did not affect ULBP expres-
sion (unpublished data). This is consistent with other observa-
tions in various human melanoma cell lines that CEACAM1 
expression correlates inversely with MICA/B but not ULBP 
expression (Fig. 4). To further confirm that the reduction in 
MICA/B expression as a consequence of CEACAM1 expres-
sion was biologically significant, we analyzed the sensitivity of 
pcDNA3 (vector control), CEACAM1-3L, and CEACAM1-
3S–transfected HCT-116 cells to primary NK cell–mediated 
cytolysis. These studies showed that forced expression of 
Figure 3.  Human CEACAM1 regulates  
human NKG2DL MICA/B expression and the 
sensitivity of tumor cells to NK cytolysis.  
(a) Flow cytometric analysis of CEACAM1, 
NKG2DL, and MHC-I (HLA) expression on indi-
cated tumor cells. HT29 cells were engineered, 
where indicated, to express less CEACAM1. 
HCT116 cells were engineered, where indicated, 
to express vector encoding long or short isoforms 
of CEACAM1. CC1shRNA, mouse CEACAM1 
shRNA; nonTshRNA, control nontargeting shRNA; 
Ig, isotype-matched control Ig. (b) 51Cr release 
cytotoxicity assay shows the sensitivity of indi-
cated tumor cells to NK-mediated cytolysis (mean ± 
SEM; *, P < 0.05). All results are representative  
of two or three experiments.JEM Vol. 208, No. 13  2637
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and  microRNA-mediated  degradation  (unpublished  data). 
Collectively, these studies suggest that the regulation of 
NKG2DL by CEACAM1 occurs subsequent to transcription. 
Consistent with this, we observed that B16F10 cells that do 
not constitutively express NKG2DL are not affected by si-
lencing CEACAM1 (Fig. 2 a).
We therefore investigated a role for posttranslational   
regulation of NKG2DL by CEACAM1. Because tumor cells 
have evolved mechanisms to shed NKG2DLs to escape anti-
tumor  immunity,  we  first  determined  whether  the  super-
natants of the tumor cells that expressed more CEACAM1 
exhibit more NKG2DLs. Neither mouse tumor cells (MC38) 
nor human tumor cells that express more CEACAM1 (HT29) 
shed  more  NKG2DLs  (Rae-1,  MICA/B)  than  the  tumor 
cells  that  express  less  CEACAM1  (HCT116;  unpublished 
data). We therefore hypothesized that CEACAM1 may func-
tion in a manner similar to viral proteins that retain NKG-
2DLs intracellularly (Wu et al., 2003). Indeed, using flow 
cytometry analysis (Fig. 5 a) we observed that whereas cell 
surface expression of Rae-1 was increased in CEACAM1-
silenced MC38 cells (CC1shRNA), intracellular Rae-1 pro-
tein was decreased in comparison to nonsilenced MC38 cells 
(nonTshRNA). These reciprocal changes in cell surface and 
intracellular expression of Rae-1 upon CEACAM1 silencing 
of MC38 cells were confirmed by fluorescence microscopy 
(Fig. 5 b). We previously demonstrated that CEACAM1 can 
associate with adaptor protein 1, which facilitates surface 
molecule expression (Nakajima et al., 2002). We determined 
whether  CEACAM1  promotes  Rae-1  internalization. We 
found  that  the  internalization  rate  of  Rae1  expressed  on 
CEACAM1-silenced and nonsilenced MC38 cells was not 
significantly different (unpublished data). We therefore exam-
ined the biochemical properties of Rae-1 in CEACAM1-
silenced MC38 cells.
that the transcriptional levels of mouse NKG2DL Rae-1 and 
MULT1 (unpublished data) were not regulated by silencing 
CEACAM1. In addition, we did not detect significant changes in 
the levels of possible human NKG2DL (MICA and MICB; 
Stern-Ginossar et al., 2007) and mouse NKG2DL (Rae-1) 
microRNAs (http://www.microrna.org) in CEACAM1-
silenced and nonsilenced HT-29 cells and MC38 cells, further 
ruling out the possibility that the unchanged mRNA levels 
reflected a balance between an increased transcription rate 
Figure 4.  Human tumor cell lines inversely express CEACAM1 and 
MICA/B. (a) Flow cytometry analysis of CEACAM1, MICA/B, and ULBP 
expression on representative human melanoma cell lines (UACC 62 and 
MD-AMB435S). Ig, isotype-matched control Ig. (b) 51Cr cytotoxicity assay 
show the sensitivity of indicated target cells to primary human NK cell–
mediated cytolysis (mean ± SEM **, P < 0.01). (c) Blocking assay of 
NKG2D-mediated in vitro cytolysis of tumor cells by indicated antibodies 
(mean ± SEM *, P < 0.05; **, P < 0.01). All results are representative of two 
or three experiments.
Figure 5.  CEACAM1 mediates intra-
cellular retention of NKG2DL. (a) Flow cyto-
metric analysis shows cell surface and 
intracellular Rae-1 expression in indicated 
tumor cells. (b) Fluorescence microscopy analy-
sis shows Rae-1(red) localization detected by 
goat anti-Rae1 followed by rhodamine- 
conjugated mouse anti–goat IgG in CEACAM1- 
silenced (CC1shRNA) and nonsilenced 
(nonTshRNA) MC38 tumor cells (bars: left two 
panels, 100 mm; right panel, 20 mm). (c) Immuno-
blot (IB) shows Rae-1 structure in indicated 
tumor cells (H, high molecular weight; L, low 
molecular weight). (d) Immunoblot analysis 
shows MHC class I expression in CEACAM1-
silenced (CC1shRNA) and nonsilenced (non-
TshRNA) MC38 tumor cells. (e) CEACAM1-silenced 
(CC1shRNA) and nonsilenced (nonTshRNA) 
cells were labeled with membrane imperme-
able biotin. Rae-1 was precipitated with  
Rae-1–specific antibody (T-IP) or streptavidin (B-IP) and detected with Rae-1–specific antibody. (f) The immunoblot (IB) shows the patterns of Rae-1  
immunoprecipitated (IP) from CEACAM1-silenced and nonsilenced cell lysates followed by mock treatment (CTL: control) or treatment with either  
Endo-H or PNGase F (PNG-F). All results are representative of three or four independent experiments, respectively.2638 CEACAM1 reduces NKG2D ligand abundance on tumors | Chen et al.
poor prognosis. Moreover, in their totality, they advance 
the notion that CEACAM1 not only serves a role as a suppres-
sor of tumor cell growth but also an important regulator of 
immune surveillance capability, with its attendant therapeutic 
implications.
MATERIALS AND METHODS
Mice and tumor assays. WT C57BL/6 (B6) and RAG2-deficient (Rag2/, 
B6) mice were purchased from Charles River Laboratories or Taconic 
Farms Inc., respectively. Ceacam1/ mice on the C57BL/6 background 
have been previously described (Leung et al., 2006). All mice were used   
between 8 and 12 wk of age. For in vivo NKG2D-blocking experiments, 
Rag2/, B6 mice were treated with anti–mouse NKG2D mAb (C7 clone; 
eBioscience) or control Ig mAb (200 µg i.p.) on days 1, 0, 1, 7, and 12 after 
tumor inoculation. Tumor cells 105 cells per injection were inoculated sub-
cutaneously (for tumor size measurement) in the right and left flanks in 100 µl 
PBS. We measured the tumor size as indicated with a metric caliper. Mice 
were maintained under specific pathogen–free conditions at the Animal 
Facilities of Harvard Medical School. All animal experimentation was per-
formed in accordance with institutional guidelines and Institutional Animal 
Care and Use Committee of Harvard Medical School, which granted per-
mission for this study.
Cell culture. MC38, B16F10, HT29, HEK293, HCT-15, and HCT116 
cells were from the American Type Culture Collection. T. Kupper (Brigham 
and Women’s Hospital, Boston, MA) provided the UACC62 and MD-
AMB435S melanoma cell lines. All cells were cultured in RPMI-1640 
medium supplemented with 10% FBS, ampicillin, streptomycin, 10 mM 
Hepes, and 3 µM -ME.
NK cells and cytotoxicity assays. Mouse and human primary NK cells 
were isolated from mouse spleens and human leukopacks (Blood Donor 
Center, Brigham and Women’s Hospital), respectively, with corresponding 
NK cell isolation kits (Miltenyi Biotec) according to the manufacturer’s 
instruction. In some experiments, the effector cells were pretreated with 
anti-NKG2D-blocking antibodies (R&D Systems) as indicated, for 30 min 
at 4°C. A standard 4-h 51Cr (PerkinElmer) release cytotoxicity assay and 
calculation of percentage of specific cytolysis were performed as described 
previously (Chen et al., 2008).
Immunoprecipitation and Western blotting. Immunoprecipitation and 
Western blotting were performed as previously described by using specific 
antibodies as indicated (Chen et al., 2008). For Rae-1 deglycosylation, the 
immunoprecipitates  were  denatured,  treated  with  Endo-H  or  PNGase   
F according to the manufacturer’s instructions (New England Biolabs), and 
analyzed by Western blotting with anti–Rae-1–specific antibody (R&D 
Systems).  For  cell  surface  immunoprecipitation,  cells  were  incubated   
with anti–Rae-1 on ice for 1 h and free antibodies were removed by ex-
tensive  washing  with  PBS,  lysed,  and  precipitated  by  adding  protein   
G–conjugated Sepharose beads. For cell surface protein biotinylation, cells 
were  labeled  with  EZ-Link  sulfo-NHS-biotin  (Thermo  Fisher  Scientific)   
according to the manufacturer’s instructions. The cell lysates were either   
immunoprecipitated with streptavidin beads or immunoblotted with an 
anti–Rae-1 antibody.
RNA silencing, detection, and protein expression. Lentiviral particles 
of shRNA specific for mouse and human CEACAM1, as well as nontar-
geting shRNA, were purchased from Sigma-Aldrich. Transduction was 
performed  according  to  the  manufacturer’s  instructions.  Clones  were   
selected with puromycin. Rae-1 RNA was detected by RT-PCR or quan-
titative PCR (qPCR) with primers as follows: forward, 5-TCCGCAAAGC-
CAGGGCCAAA-3, and reverse, 5-GCTGGTAGGTGGAAGCGGGG-3. 
MULT1 was detected by qPCR with primers as follows: forward, 5-GCAG-
GCTGAGGTGTGTGGCC-3, and reverse, 5-CCAGGTCCTGCAGTC-
GCCCT-3 on a LightCycler 480 qPCR machine (Roche).
As shown in Fig. 5 c, the Rae-1 protein that was ex-
pressed when CEACAM1 was silenced was characterized by 
a significantly higher molecular weight (H, arrow) than that 
observed in nonsilenced MC38 cells (L, arrow). Notably, the 
molecular weight of MHC class I proteins in CEACAM1- 
silenced and nonsilenced MC38 cells was identical (Fig. 5 d), 
indicating CEACAM1 specifically targets structural modifi-
cations in Rae-1. To determine whether this high molecular 
weight isoform of Rae-1 was responsible for the increased 
cell surface expression of Rae-1 observed when CEACAM1 
was silenced (Fig. 5 a), we separately labeled the cell surface 
proteins of the same numbers of CEACAM1-silenced and 
nonsilenced MC38 cells with cellular membrane imperme-
able biotin, precipitated the biotinylated cell surface proteins 
from cellular lysates with streptavidin beads or anti–Rae-1 
antibody followed by protein G–conjugated Sepharose beads, 
and detected Rae-1 by immunoblotting with an anti–Rae-1–
specific antibody. By this method, the high molecular weight 
form of Rae-1 was biochemically detectable on the cell 
surface of CEACAM1-silenced MC38 cells and undetectable 
on CEACAM1-nonsilenced cells (Fig. 5 e.) This suggested 
that silencing CEACAM1 expression in MC38 cells resulted 
in increased cell surface expression of Rae-1 that might pos-
sess an increased quantity of carbohydrate side-chain modifi-
cations in comparison to CEACAM1 nonsilenced cells, in 
which Rae-1 was observed to accumulate intracellularly as 
an incompletely glycosylated protein. This was indeed con-
firmed  by  performing  Endoglycosidase-H  (Endo-H)  and   
N-glycanase (PNGase F) digestion of anti–Rae-1 immuno-
precipitates obtained from CEACAM1-silenced and nonsi-
lenced  cells  (Fig.  5  f). Whereas  the  high  molecular  band 
observed in CTL (control) samples was sensitive to Endo-H, 
the low molecular weight bands were resistant to Endo-H 
but sensitive to N-glycanase (Fig. 5 f). Collectively, these 
studies show that CEACAM1 retards Rae-1 intracellularly 
by  disabling  its  full  decoration  with  N-linked  glycans, 
leading to insensitivity of tumor cells to NK cell–mediated 
immune responses.
We also examined the biochemical structure of MICA/B 
in HCT116 and HT29 cells in the context of different levels 
of CEACAM1 to determine whether the mechanism of 
CEACAM1-induced retention of MICA/B in human cells 
was the same as that observed in mouse cells. However, the 
molecular weight of MICA/B were the same in HCT116 
and HT29 cell lines and not altered by the levels of CEACAM1 
expression (unpublished data). These studies indicate that 
human  CEACAM1  employs  an  alternative  mechanism  to 
down-regulate MICA/B surface expression consistent with 
the  diversity  and  complexity  of  NKG2DL  structure  and 
transport (Coudert and Held, 2006; Arapovic et al., 2009; 
Champsaur and Lanier, 2010).
Collectively, we have demonstrated a role for CEACAM1 
in the attenuation of immune surveillance by down-regulation 
of NKG2DL expression on tumor cells. These findings are 
consistent with accumulating clinical observations that elevated 
expression of CEACAM1 on tumor cells correlates with a JEM Vol. 208, No. 13  2639
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Fluorescence microscopy. CEACAM1 silenced and nonsilenced MC38 
cells were seeded on coverslips. Rae1 (both cell surface and intracellular) 
was detected by goat anti-Rae1 (R&D Systems), followed by rhodamine-
conjugated mouse anti–goat IgG using a Nikon Eclipse Ti-U fluorescence 
microscope and NIS Elements v3.1 image-processing software.
Flow cytometry. For CEACAM1 expression analysis, cells were incubated 
with  CC1  (mouse  anti–mouse  CEACAM1  monoclonal  antibody  (a  gift 
from K. Holmes, University of Colorado, Denver, CO; Dveksler et al., 
1993)  or  5F4  (mouse  anti–human  CEACAM1  monoclonal  antibody; 
Morales et al., 1999) for 20 min, followed by FITC-conjugated rat anti–
mouse  IgG1  (Jackson  ImmunoResearch  Laboratories).  For  detection  of 
Rae-1,  MULT1,  H-60,  ULBP,  MICA/B  surface  expression  cells  were 
stained with FITC-conjugated anti–Rae-1 (R&D Systems), PE-conjugated 
anti-MULT1  (R&D  Systems),  PE-conjugated  anti-H60  (eBioscience),   
PE-conjugated anti-ULBP (R&D Systems), and PE-conjugated anti-MICA/B 
(R&D Systems) antibodies, respectively. For intracellular Rae-1 staining, 
cells were stained with nonconjugated anti–Rae-1 (R&D Systems) for 30 min, 
fixed with Cytofix buffer (BD), permeabilized with Cytofix/perm buffer 
(BD), and then stained with the aforementioned FITC-conjugated anti-
Rae1 antibody (R&D Systems). Stained cells were analyzed on a FACScan 
(BD). For Rae-1 internalization, cells are preincubated with nonconjugated 
rat anti-Rae-1 for 1 h at 4°C. Free antibodies were removed by washing 
cells twice with medium. Cells were then placed in 37°C for the indicated 
times and stained with FITC-conjugated goat anti–rat Ig. Percentage of 
mean fluorescence intensity (MFI) was calculated as MFI (t)/MFI (0 h) × 100.   
t indicates time point.
Statistics. A Student’s t test (paired, two-tailed) was used to determine 
significance. A p-value of <0.05 was considered as significant.
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